Semaglutide use and mood disorders in women with multiple hormonal and metabolic problems

A retrospective cohort study evaluates whether semaglutide use in patients with polyendocrine metabolic ovarian syndrome (PMOS) is associated with an increased risk of mood disorders.

• The study compares mood disorder risk in patients with PMOS treated with semaglutide versus those treated with metformin.
• A large, propensity-matched dataset from TriNetX was utilized for the analysis.
• Findings may indicate differences in mood disorder risk between the two treatment groups.
• The outcomes related to mood disorders are preliminary and require further investigation.

Simplified